Viral Infections
RSSArticles
-
Long-Term Successful Virological Suppression with Dolutegravir Monotherapy in the EARL-SIMPLIFIED Trial
Dolutegravir monotherapy was demonstrated to be non-inferior as compared with combination antiretroviral therapy in EARLY-SIMPLIFIED, a randomized, controlled trial with long-term follow-up that included a highly selected group of people with HIV-1 infection.
-
A Comparison of Sequelae After Hospitalization with COVID-19, Influenza, or Sepsis
The incidence of most selected new-onset medical conditions did not significantly differ among those who had been hospitalized with COVID-19, influenza, or sepsis.
-
Post-Exposure Rabies Prophylaxis — Shorter, Simpler, and Less Costly
After bites by animals potentially infected with rabies, three-visit (over one week) intradermal rabies vaccination was compared to standard four-visit (over two weeks) intramuscular rabies vaccination. Both vaccine regimens prompted similarly protective neutralizing antibody and T-cell responses. While still off-label, the shorter, simpler regimen could protect patients at lower cost than the current standard regimen.
-
APIC 2023 Keynote: IPs Must Reclaim Their Power
The 2023 APIC keynote speaker called for infection preventionists to reclaim their narrative, to tell people what they do in no uncertain terms, and to empower others to do likewise.
-
Mothers, Babies, and HPV: Thanks for Not Sharing!
Nearly half of pregnant women in a Canadian study had vaginal swabs positive for human papillomavirus (HPV) deoxyribonucleic acid (DNA). Only about one-fourth of placentas and newborns produced by those HPV-positive women carried detectable HPV DNA, and all HPV-positive babies had cleared their positivity by 6 months of age.
-
Vaccination Against Mpox Is Effective
Two-dose vaccination with Jynneos is effective in the prevention of mpox (monkeypox), but a better vaccine is desirable, particularly for use in immunocompromised individuals.
-
Induction Therapy for HIV/AIDS-Related Disseminated Histoplasmosis with Single High-Dose Liposomal Amphotericin B
In a Phase II randomized clinical trial involving 118 participants in Brazil with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related disseminated histoplasmosis, induction therapy with single high-dose (10 mg/kg) liposomal amphotericin B was safe and non-inferior as compared with standard dose (3 mg/kg) liposomal amphotericin B given once daily for 14 days.
-
Practice Alert Provides Critical Care Nurses Safety Tips for Prone Positioning
The technique that became well known during the COVID-19 pandemic remains a standard tactic for managing acute respiratory distress syndrome.
-
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
-
Infectious Disease Alert Updates
Immunocompromised Patients with Persistent COVID-19; Endemic Mycoses Are No Longer ‘-Demic’